![Michael Seckler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Seckler
Corporate Officer/Principal at
CORMEDIX INC.
Net worth: 1 M $ as of 31/05/2026
Profile
Michael D.
Seckler is currently Director at K2 Biotechnology Ventures LLC and Chief Commercial Officer & Executive VP at CorMedix, Inc. Former positions include Chief Executive Officer & Director at Evome Medical Technologies, Inc., Director at GLyPharma Therapeutic, Inc., Vice President-Global Marketing at Ferring Pharmaceuticals, Inc. from 2017 to 2019, and Chief Operating Officer at FerGene, Inc. from 2022 to 2023.
Education includes undergraduate and MBA degrees from The Pennsylvania State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CORMEDIX INC. 0.17% | 08/01/2026 | 133,156 ( 0.17% ) | 1 M $ | 31/05/2026 |
Michael Seckler active positions
| Companies | Position | Start |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | 08/01/2026 |
K2 Biotechnology Ventures LLC
 K2 Biotechnology Ventures LLC Miscellaneous Commercial ServicesCommercial Services Engages in acceleration the commercialization of university, medical center and health care innovations | Director/Board Member | - |
Former positions of Michael Seckler
| Companies | Position | End |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Chief Operating Officer | 01/05/2023 |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets fertility and endocrinology products | Corporate Officer/Principal | - |
| EVOME MEDICAL TECHNOLOGIES INC. | Chief Executive Officer | - |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology Develops oncology therapeutic treatment | Director/Board Member | - |
Training of Michael Seckler
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
6
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
CorMedix, Inc.
 CorMedix, Inc. BiotechnologyHealth Technology Develops medical devices for cardiovascular and kidney diseases | Health Technology |
The Pennsylvania State University
 The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets fertility and endocrinology products | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology Develops oncology therapeutic treatment | Health Technology |
Evome Medical Technologies, Inc.
 Evome Medical Technologies, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes medical devices used for pain management and physical therapy treatments and isokinetic dynamometer | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
K2 Biotechnology Ventures LLC
K2 Biotechnology Ventures LLC Miscellaneous Commercial ServicesCommercial Services Engages in acceleration the commercialization of university, medical center and health care innovations | Commercial Services |
- Stock Market
- Insiders
- Michael Seckler
